BOSTON, SHANGHAI, and SUZHOU — December 8, 2025, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced the closing of Series B financing round, raising over $110 million. The financing will advance its clinical stage assets towards registrational studies and accelerate the development of programs across several therapeutic areas, powered by its industry-leading RNAi technologies including the LEAD™ (Ligand and Enhancer Assisted Delivery) delivery platform.
The Series B financing was led by a well-known industrial investor, with participation from an international sovereign wealth fund, Sino Biopharm, Legend Capital, Vivo Capital, Invus, SymBiosis, Guofa Capital, TruMed, and Lake Bleu Capital; strategic investment from Eli Lilly and Company; and continued support from existing shareholders including Qiming Venture Partners, K2 Venture Partners, TF Capital, Oriza Holdings, Northern Light Venture Capital, among others.
Since its inception in 2021, SanegeneBio has established proprietary RNAi platform enabling first- or best-in-class RNAi therapeutics targeting both liver and extrahepatic tissues, based on which it has built a diversified pipeline including multiple clinical-stage programs across autoimmune, cardiovascular, metabolic diseases and obesity. The successful completion of the Series B financing will further accelerate and globally expand ongoing and planned clinical studies, while supporting continued breakthroughs in RNAi technology.
Dr. Weimin Wang, Founder and Chief Executive Officer of SanegeneBio, stated:
“The successful closing of the Series B round represents a significant milestone in SanegeneBio’s development footprint. We are honored to have the support from leading global institutional investors, showing their confidence and recognition of our R&D strength and corporate vision, while providing important resources for our long-term growth. We remain committed to addressing global unmet medical needs by continuously innovating to expand the frontier of RNAi technologies. Moving forward, we plan to advance our investigational medicines to late-stage development globally, and bring more transformative programs into the clinic leveraging our LEAD TM platform .”
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage on LinkedIn.